The Quiet Consolidation Reshaping GI Medicine
Gastroenterology has become one of private equity’s most active acquisition targets in American medicine, and most patients have no idea it’s happening. Across the country, small and mid-sized GI practices – the kind built by one or two physicians over decades of community medicine – are receiving acquisition offers, signing letters of intent, and folding into larger management platforms with names patients will never recognize. The deals are structured quietly, announced rarely, and completed quickly.
The appeal is straightforward from a financial standpoint. Gastroenterology generates high procedural volume, operates largely in outpatient settings, and benefits from a predictable patient pipeline tied to colonoscopy screening guidelines alone. When you combine those economics with an aging population and a physician workforce that skews older, you get a specialty ripe for consolidation. PE firms recognized this years ago. The acquisition wave is now well underway.
Why GI Practices Are Selling Now
The decision to sell is rarely just financial, though the money matters. Physicians who built independent practices over 20 or 30 years are approaching retirement age without obvious succession plans. Recruiting younger gastroenterologists into private practice has grown harder as medical school graduates increasingly prefer the stability of employed positions. A solo or small group practice that cannot recruit its next generation of physicians faces a slow erosion of value – and many owners would rather convert that equity into a liquidity event than watch it decline.
Administrative burden is the other pressure point. Billing complexity, prior authorization volume, EHR maintenance costs, and compliance requirements have grown to a point where the overhead of running an independent practice can consume a physician’s attention in ways that make clinical work feel secondary. PE-backed platforms offer to absorb those burdens through centralized management infrastructure. For a physician who simply wants to see patients and stop managing a business, that offer carries real weight.
How the Rollup Model Actually Works
Private equity firms do not typically buy individual GI practices outright and hold them. The strategy is to acquire a platform – often a larger regional group – and then bolt smaller practices onto it through add-on acquisitions. Each acquisition builds scale, which improves the platform’s negotiating leverage with insurers and reduces per-unit costs. The goal is to grow the platform to a size that makes it attractive for a sale to a larger PE fund or a strategic buyer, typically within a five-to-seven year window.
Physician sellers in these deals usually receive a mix of cash at closing and equity in the combined platform. That equity component is often described as a “second bite of the apple” – the idea being that when the platform eventually sells at a higher multiple, early sellers benefit again. Whether that second payout materializes depends entirely on how the platform performs under PE management, which introduces uncertainty that the initial transaction documents rarely make obvious.
The valuation multiples being offered have been high enough to attract physicians who were previously skeptical of outside ownership. GI practices in attractive markets have reportedly traded at EBITDA multiples that would have seemed unlikely a decade ago. That premium reflects competition among PE firms for a limited number of quality targets, and it creates a sense of urgency in the market – physicians who wait may receive lower offers as consolidation matures and competition among buyers thins.
Management service organizations, or MSOs, are typically the legal structure through which PE firms control these platforms without technically owning the clinical practice – a workaround designed to navigate corporate practice of medicine laws that vary by state. The physician entity retains nominal control over clinical decisions, while the MSO controls billing, staffing, real estate, and capital allocation. The line between administrative and clinical authority can blur in practice, which is one reason medical associations have raised ongoing concerns about these structures.
What Physicians Give Up
Independence is the most obvious cost, and physicians who have sold into rollups describe a spectrum of experiences. Some report that day-to-day clinical life changed little, at least initially. Others describe scheduling pressure, productivity quotas, and a reduced ability to make practice-level decisions that had previously been routine. The variation tracks closely with how aggressively the acquiring platform manages for margin versus how much autonomy it extends to acquired physicians.
Employment contracts in these transactions typically include non-compete clauses and restrictive covenants that limit a physician’s options if the relationship sours. A gastroenterologist who sells a practice and later finds the working environment untenable may face legal restrictions on practicing in the same geography for a defined period. That leverage asymmetry is built into the deal structure from day one, and it shifts significantly once the transaction closes.
The Patient Side of the Equation
For patients, the visible changes after a PE acquisition are often minimal – the same office, the same doctors, the same front desk staff. What shifts is less visible: how appointment capacity is managed, which ancillary services get prioritized, and how aggressively the practice pursues in-network versus out-of-network billing arrangements. PE-backed GI platforms have financial incentives to grow procedure volume and ancillary revenue, which can align with good patient care or create friction with it, depending on how the platform is run.
Ambulatory surgery centers attached to GI practices are a particular focus of PE interest because they generate facility fees on top of professional fees. A platform that owns both the physician group and the ASC captures a significantly larger share of revenue per procedure. This is legal and common, but it does create a financial structure where the platform benefits from higher procedure volume in ways that an independent physician practice historically did not.
The dynamic playing out in gastroenterology is not isolated – regional pain management clinics have been moving through a nearly identical consolidation cycle, with the same PE playbook applied to a different procedural specialty. The common thread is outpatient volume, predictable reimbursement, and an older physician workforce without clean succession paths. Gastroenterology checks all three boxes more completely than almost any other specialty, which is why the pace of deal activity has accelerated rather than slowed.
What remains unresolved is how the market behaves once consolidation matures. As fewer independent GI practices remain available to acquire, platform growth slows and the financial rationale for holding the asset weakens. PE funds have defined timelines. When exit windows arrive, the platforms move to new owners – often larger PE funds or, increasingly, health systems looking to acquire outpatient specialty capacity. The physicians who sold into the first transaction may find themselves working for a third or fourth owner within a decade, each transition carrying its own terms and its own priorities.
